Literature DB >> 28166598

Scoring Systems for Estimating Risk of Venous Thromboembolism in Hospitalized Medical Patients.

Sofia Barbar1, Paolo Prandoni2.   

Abstract

Deep vein thrombosis and pulmonary embolism are associated with considerable morbidity and mortality in hospitalized patients, accounting for up to 10% of hospitalization-related deaths in both surgical and medical patients. Pharmacologic thromboprophylaxis has been demonstrated to be effective, safe, and cost-effective in preventing hospital-acquired venous thromboembolism (VTE) among medical inpatients, and clinician awareness of thrombotic risk promotes prescription of thromboprophylaxis. Guidelines recommend stratification of thrombotic risk for all patients and, unless contraindicated, administration of VTE prophylaxis. Based on several recognized predisposing and exposing risk factors for VTE, several scoring systems have been published in the past 15 years. Borrowing models developed in the surgical setting, recognized risk factors for VTE complications in medical inpatients have been combined in different weighted scores and derived and validated in heterogeneous medical populations. Although the perfect score, balancing thrombotic and hemorrhagic risk, has probably not yet been built, the adoption of an easy-to-use risk assessment model has the potential to support physicians in properly stratifying VTE risk in medical inpatients, tailoring thromboprophylaxis prescription. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2017        PMID: 28166598     DOI: 10.1055/s-0036-1597901

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  5 in total

1.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.

Authors:  Holger J Schünemann; Mary Cushman; Allison E Burnett; Susan R Kahn; Jan Beyer-Westendorf; Frederick A Spencer; Suely M Rezende; Neil A Zakai; Kenneth A Bauer; Francesco Dentali; Jill Lansing; Sara Balduzzi; Andrea Darzi; Gian Paolo Morgano; Ignacio Neumann; Robby Nieuwlaat; Juan J Yepes-Nuñez; Yuan Zhang; Wojtek Wiercioch
Journal:  Blood Adv       Date:  2018-11-27

Review 2.  Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.

Authors:  Susan R Kahn; David R Morrison; Gisèle Diendéré; Alexandre Piché; Kristian B Filion; Adi J Klil-Drori; James D Douketis; Jessica Emed; André Roussin; Vicky Tagalakis; Martin Morris; William Geerts
Journal:  Cochrane Database Syst Rev       Date:  2018-04-24

3.  Assessing the Risk for Development of Deep Vein Thrombosis among Chinese Patients using the 2010 Caprini Risk Assessment Model: A Prospective Multicenter Study.

Authors:  Haixin Bo; Yilin Li; Ge Liu; Yufen Ma; Zhen Li; Jing Cao; Ying Liu; Jing Jiao; Jiaqian Li; Fangfang Li; Hongpeng Liu; Chen Zhu; Huaping Liu; Baoyun Song; Jingfen Jin; Yilan Liu; Xianxiu Wen; Shouzhen Cheng; Xia Wan; Xinjuan Wu
Journal:  J Atheroscler Thromb       Date:  2019-12-17       Impact factor: 4.928

4.  High rate of bleeding and arterial thrombosis in COVID-19: Saudi multicenter study.

Authors:  Abdulrahman Al Raizah; Ahmed Al Askar; Naila Shaheen; Khalid Aldosari; Mohamed Alnahdi; Musumadi Luhanga; Turki Alshuaibi; Wail Bajhmoum; Khaled Alharbi; Ghaida Alsahari; Hadeel Algahtani; Eunice Alrayes; Abdulrahim Basendwah; Alia Abotaleb; Mosaad Almegren
Journal:  Thromb J       Date:  2021-03-03

5.  Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study.

Authors:  Matteo Giorgi-Pierfranceschi; Oriana Paoletti; Angelo Pan; Fabio De Gennaro; Anna Laura Nardecchia; Rossella Morandini; Claudia Dellanoce; Samuele Lombi; Maurizio Tala; Vanessa Cancelli; Silvia Zambelli; Giancarlo Bosio; Laura Romanini; Sophie Testa
Journal:  Intern Emerg Med       Date:  2020-08-25       Impact factor: 5.472

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.